Junctional epidermolysis bullosa (medicine)

debra of America Raises $600,000 at Annual Benefit; Honors Trailblazers in Epidermolysis Bullosa Community

Retrieved on: 
Friday, November 10, 2023
Medicine, Health, Courage, Research, EBS, King County Superior Court, Therapy, Epidermolysis bullosa, Blister, Disease, Abrasion (medical), 34th Independent Spirit Awards, Patient, Genetic disorder, COL7A1, U.S. FDA, FDA, Epidermolysis bullosa dystrophica, EB, Partner, DEBRA, Conference, MD, Trauma, Survival, DEB, Junctional epidermolysis bullosa (medicine), Skin, Quality of life, Georgia Aquarium, Independent Spirit Awards, Government, Life, Legislation, Superior court, Policy, Pharmaceutical industry, Nursing

Funds raised help advance EB research initiatives and directly support families and individuals living with EB.

Key Points: 
  • Funds raised help advance EB research initiatives and directly support families and individuals living with EB.
  • At the benefit, debra honored several EB trailblazers for their research and therapeutic contributions as well as individuals living with the disease.
  • Krystal Biotech was recognized for its work in developing VYJUVEK™ (beremagene geperpavec-svdt), the first FDA-approved treatment of Dystrophic Epidermolysis Bullosa (DEB).
  • Epidermolysis Bullosa is a rare genetic disorder characterized by fragile skin that easily blisters or forms painful sores from minor friction or trauma.

United States Epidermolysis Bullosa Market Analysis and Competitive Landscape Report 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 21, 2022
Health, Pharmaceutical, Junctional epidermolysis bullosa (medicine), Research, Competitive landscape, Epidemiology, View, Fine chemical, Risk management, Pharmaceutical industry, Epidermolysis bullosa

The "US Epidermolysis Bullosa Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Epidermolysis Bullosa Market and Competitive Landscape - 2022" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive insights into Epidermolysis Bullosa pipeline products, Epidermolysis Bullosa epidemiology, Epidermolysis Bullosa market valuations and forecast, Epidermolysis Bullosa drugs sales and competitive landscape in the US.
  • Epidermolysis Bullosa pipeline: Find out the products in clinical trials for the treatment of Epidermolysis Bullosa by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Epidermolysis Bullosa drugs: Identify key products marketed and prescribed for Epidermolysis Bullosa in the US, including trade name, molecule name, and company
    Epidermolysis Bullosa market valuations: Find out the market size for Epidermolysis Bullosa drugs in 2021 in the US.
  • Find out how the market advanced from 2019 and forecast to 2027
    Epidermolysis Bullosa drugs market share: Find out the market shares for key Epidermolysis Bullosa drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Epidermolysis Bullosa products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005560/en/

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

Retrieved on: 
Monday, July 25, 2022
Data monitoring committee, NIH, Epidermolysis bullosa simplex, Skin, GLOBE, Epidermolysis bullosa, INM, DMC, U.S. Securities and Exchange Commission, EB, Research, Ageing, Junctional epidermolysis bullosa (medicine), Person, Health, Patent, Adult, Safety, News, Kindler syndrome, Clinical trial, Review, CBN, Disease, Company, Senior, Gastrointestinal tract, Patient, Adolescence, Nasdaq, Cannabinoid, INMED, Therapy, Annual report, EBS, Cannabinol, Security, Risk, Pharmaceutical industry

The inclusion of adolescents will have a positive impact in the enrollment rate for the remainder of the clinical trial.

Key Points: 
  • The inclusion of adolescents will have a positive impact in the enrollment rate for the remainder of the clinical trial.
  • With the DMC approval to enroll adolescent patients into InMeds INM-755 Phase 2 clinical trial, the first adolescent patient with EB has been enrolled into the clinical trial and has completed treatment at the clinical site in Greece.
  • This patent allows for the use of topically administered CBN in patients with epidermolysis bullosa simplex (EBS).
  • InMeds Phase 2 clinical trial now has eight clinical trial sites fully activated to screen and enroll patients.

Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022

Retrieved on: 
Thursday, July 7, 2022
JEB, Department, FDA, Patient, DEB, SPD, EB, Epidermolysis bullosa, European Commission, Degenerative disease, Ford 4.4 Turbo Diesel, Pain, BSAP, Wound healing, EASE, Clinical trial, Royal commission, University, Colorado School of Public Health, OLP, MD, Junctional epidermolysis bullosa (medicine), Pharmaceutical industry, Medical imaging, Healthcare, EU

EASE ( NCT03068780 ), the largest clinical trial in Epidermolysis Bullosa (EB), is a Phase 3, randomized, controlled, 90-day double-blind, efficacy and safety study of Oleogel-S10 (birch triterpenes) in patients with inherited EB, followed by a 24-month open-label single-arm phase.

Key Points: 
  • EASE ( NCT03068780 ), the largest clinical trial in Epidermolysis Bullosa (EB), is a Phase 3, randomized, controlled, 90-day double-blind, efficacy and safety study of Oleogel-S10 (birch triterpenes) in patients with inherited EB, followed by a 24-month open-label single-arm phase.
  • We are committed to working with other regulatory agencies, including the FDA, to enable more patients to avail of this treatment.
  • The proportion of DEB patients with target wound closure within 45 days was 44.3% on Oleogel-S10 versus 29.6% on control gel (p=0.017).
  • The EASE trial (NCT03068780) is the largest ever global Phase 3 trial conducted in patients with EB, performed across 58 sites in 28 countries.

Results of Annual General Meeting

Retrieved on: 
Friday, July 1, 2022
FDA, Lipodystrophy, Patient, Lists of diseases, Metreleptin, EC, EB, COVID-19, Acromegaly, Degenerative disease, Octreotide, Company, Mass meeting, EMA, Birth, Investment, Environment, Diet, Annual general meeting, Lomitapide, GL, Forward-looking statement, Pharmaceutical industry, Dietary supplement, EU, Junctional epidermolysis bullosa (medicine)

DUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at yesterdays Annual General Meeting were duly passed.

Key Points: 
  • DUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at yesterdays Annual General Meeting were duly passed.
  • The full text of each resolution was included in the notice of the General Meeting posted to shareholders on June 1, 2022, and is available on the Company's website www.amrytpharma.com .
  • Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance.
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Retrieved on: 
Monday, June 27, 2022
FDA, Lipodystrophy, Patient, Lists of diseases, CEO, Royal College of Surgeons in Ireland, Novartis, Metreleptin, EB, EC, COVID-19, Acromegaly, Degenerative disease, Octreotide, Development, CMO, EMA, Birth, Investment, Environment, Diet, Physician, Head, VP, Royal college, Lomitapide, GL, Forward-looking statement, Pharmaceutical industry, Dietary supplement, EU, AstraZeneca, Junctional epidermolysis bullosa (medicine)

DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect.

Key Points: 
  • DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect.
  • Dr Cunningham joined Amryt in April 2020 as VP, Head of Development with responsibility for pre-clinical and clinical development of the Amryt portfolio.
  • Dr Joe Wiley, CEO of Amryt Pharma, commented: I am very pleased to announce Tracys appointment as our CMO.
  • Tracy also brings a wealth of experience from other roles she has held in her career prior to joining Amryt.

Posting of Annual Report and Notice of AGM

Retrieved on: 
Wednesday, June 1, 2022
Proxy, Lipodystrophy, Lists of diseases, EB, Acromegaly, EMA, European, Forward-looking statement, Environment, Octreotide, Investment, Lomitapide, Metreleptin, Shareholder, CHMP, FDA, Patient, COVID-19, Birth, Diet, AGM, GL, Dietary supplement, Pharmaceutical industry, Junctional epidermolysis bullosa (medicine), EU

Shareholders using the telephone facility should, therefore, also submit their Form of Proxy by the relevant deadline in advance of the AGM.

Key Points: 
  • Shareholders using the telephone facility should, therefore, also submit their Form of Proxy by the relevant deadline in advance of the AGM.
  • Amryt comprises a strong and growing portfolio of commercial and development assets.
  • Mycapssa has also been submitted to the EMA and is not yet approved in Europe.
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

Amryt Announces Details of EMA Contingent Value Rights Payment

Retrieved on: 
Tuesday, May 17, 2022
Deed poll, USD, Loan note, CHMP, EMA, Diet, Lipodystrophy, EB, Investment, Degenerative disease, Birth, European, COVID-19, Lomitapide, Octreotide, Link group, GL, Acquisition, Company, Holder, European Medicines Agency, Deed, Lists of diseases, Somatostatin, Nasdaq, Environment, Patient, Acromegaly, Metreleptin, Forward-looking statement, Contingent value rights, Pharmaceutical industry, Security (finance), Dietary supplement, Junctional epidermolysis bullosa (medicine), EU

Each CVR Holder will be issued with one loan note of USD$0.0995 for each CVR they hold (each a Loan Note).

Key Points: 
  • Each CVR Holder will be issued with one loan note of USD$0.0995 for each CVR they hold (each a Loan Note).
  • The total amount due to each CVR Holder will be paid by cheque on the Payment Date.
  • Amryt alsointends to develop oral medications that are currently only available as injectable therapies through itsTransient PermeabilityEnhancer (TPE) technology platform.For more information on Amryt, including products, please visit www.amrytpharma.com .
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

Amryt Announces New Patent for Mycapssa®

Retrieved on: 
Wednesday, May 11, 2022
Approved Drug Products with Therapeutic Equivalence Evaluations, EB, COVID-19, United States patent law, Forward-looking statement, Investment, Birth, Metreleptin, Diet, EMA, Nasdaq, Approved drug, GL, Lipodystrophy, Patient, Lomitapide, Degenerative disease, Environment, Patent, Octreotide, CHMP, European, Somatostatin, Acromegaly, Lesbian flag, Lists of diseases, Orange Book, USPTO, Pharmaceutical industry, Dietary supplement, EU, Junctional epidermolysis bullosa (medicine)

The USPTO has issued to Amryt a notice of allowance for US Patent Application No.

Key Points: 
  • The USPTO has issued to Amryt a notice of allowance for US Patent Application No.
  • Amryt will have nine Orange Book-listed patents for Mycapssa with patent protection through December 2040.
  • Amryt alsointends to develop oral medications that are currently only available as injectable therapies through itsTransient PermeabilityEnhancer (TPE) technology platform.For more information on Amryt, including products, please visit www.amrytpharma.com .
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

Amryt to Report Q1 2022 Results on May 4, 2022

Retrieved on: 
Thursday, April 14, 2022
EMA, GL, Lomitapide, EB, COVID-19, Birth, Acromegaly, Patient, Metreleptin, 353, Diet, Octreotide, Environment, Forward-looking statement, Investment, Lipodystrophy, FDA, Lists of diseases, BST, Dietary supplement, Pharmaceutical industry, EU, Junctional epidermolysis bullosa (medicine)

A playback facility will be available from May 4, 2022 at 1330 ET/1830 BST May 11, 2022 at 1330 ET/1830 BST.

Key Points: 
  • A playback facility will be available from May 4, 2022 at 1330 ET/1830 BST May 11, 2022 at 1330 ET/1830 BST.
  • Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.
  • Amryt comprises a strong and growing portfolio of commercial and development assets.
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.